Literature DB >> 12774249

The pathological assessment of mesorectal excision: implications for further treatment and quality management.

P Hermanek1, P Hermanek1, W Hohenberger, M Klimpfinger, F Köckerling, T Papadopoulos.   

Abstract

BACKGROUND AND AIMS: Most clinical practice guidelines today recommend total mesorectal excision (TME) for carcinoma of the middle and lower rectal thirds and partial mesorectal excision (PME) for the upper rectal third. However, these procedures may not always fulfill the oncological requirements. The pathological examination of resected rectal carcinomas should always include a visual assessment of the mesorectal excision to ensure oncological adequacy and appropriate quality. The clinical practice guideline of the German Cancer Society recommends reporting of the distal extent of mesorectal excision (total or partial without coning) and the excision in an inviolate fascial envelope. PATIENTS AND METHODS: Reporting schemas of assessment and documentation for daily use and for studies are presented.
RESULTS: Careful macroscopic evaluation of the resection specimen should be standardized. This may be supplemented by stain marking after postoperative filling the inferior mesenteric or superior rectal artery with ink or methylene blue solution. Photodocumentation is highly desirable. The pathological assessment of adequacy of mesorectal excision should be taken into account in selection for adjuvant radiotherapy. Objective macro- and microscopic assessment of mesorectal excision by pathologists is essential for quality management throughout patient care and in clinical trials.

Entities:  

Mesh:

Year:  2003        PMID: 12774249     DOI: 10.1007/s00384-002-0468-6

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  35 in total

1.  Lessons from hand transplantations.

Authors:  S Hettiaratchy; P E Butler; W P Lee
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

Review 2.  Adjuvant therapy for resectable rectal adenocarcinoma.

Authors:  K S Hu; L B Harrison
Journal:  Semin Surg Oncol       Date:  2000-12

3.  Local recurrence after mesorectal excision for rectal cancer.

Authors:  A Nesbakken; K Nygaard; O Westerheim; T Mala; O C Lunde
Journal:  Eur J Surg Oncol       Date:  2002-03       Impact factor: 4.424

4.  [Laparoscopic surgery of rectal carcinoma. Radical oncology and late results].

Authors:  E Bärlehner; T Decker; S Anders; B Heukrodt
Journal:  Zentralbl Chir       Date:  2001-04       Impact factor: 0.942

5.  Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project.

Authors:  A L Martling; T Holm; L E Rutqvist; B J Moran; R J Heald; B Cedemark
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

6.  Evaluation of the role of pre-operative magnetic resonance imaging in the management of rectal cancer.

Authors:  I D Botterill; D M Blunt; P Quirke; D Sebag-Montefiore; P M Sagar; P J Finan; A G Chalmers
Journal:  Colorectal Dis       Date:  2001-09       Impact factor: 3.788

Review 7.  Neoadjuvant and adjuvant radio- and radio-chemotherapy of rectal carcinomas.

Authors:  L Påhlman
Journal:  Int J Colorectal Dis       Date:  2000-02       Impact factor: 2.571

8.  Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

Authors:  R J Heald; B J Moran; R D Ryall; R Sexton; J K MacFarlane
Journal:  Arch Surg       Date:  1998-08

9.  Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer.

Authors:  N Scott; P Jackson; T al-Jaberi; M F Dixon; P Quirke; P J Finan
Journal:  Br J Surg       Date:  1995-08       Impact factor: 6.939

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

View more
  20 in total

1.  Evaluating toxicity in neoadjuvant radio-chemotherapy of rectal cancer.

Authors:  Stefan Höcht
Journal:  Int J Colorectal Dis       Date:  2003-07-15       Impact factor: 2.571

2.  Surgery of rectal cancer: still not a science.

Authors:  Federico Bozzetti
Journal:  Int J Colorectal Dis       Date:  2003-10-03       Impact factor: 2.571

3.  Ex Vivo Intra-arterial Methylene Blue Injection in Rectal Cancer Specimens Increases the Lymph-Node Harvest, Especially After Preoperative Radiation.

Authors:  Maria Münster; Uwe Hanisch; Muin Tuffaha; Rainer Kube; Henry Ptok
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

Review 4.  The total mesorectal excision specimen for rectal cancer: a review of its pathological assessment.

Authors:  Jeremy R Parfitt; David K Driman
Journal:  J Clin Pathol       Date:  2006-10-17       Impact factor: 3.411

5.  Quality management in rectal carcinoma: what is feasible?

Authors:  Susanne Merkel; Daniela Klossek; Jonas Göhl; Thomas Papadopoulos; Werner Hohenberger; Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2009-06-02       Impact factor: 2.571

Review 6.  Comprehensive reviews of the interfascial plane of the retroperitoneum: normal anatomy and pathologic entities.

Authors:  Su Lim Lee; Young Mi Ku; Sung Eun Rha
Journal:  Emerg Radiol       Date:  2009-04-28

Review 7.  [Individualizing treatment for locally advanced rectal cancer].

Authors:  T Liersch; H Rothe; B M Ghadimi; H Becker
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

8.  Long-term oncologic outcome after laparoscopic surgery for rectal cancer.

Authors:  Ayman Agha; Volker Benseler; Matthias Hornung; Michael Gerken; Igors Iesalnieks; Alois Fürst; Matthias Anthuber; Karl-Walter Jauch; Hans J Schlitt
Journal:  Surg Endosc       Date:  2013-11-08       Impact factor: 4.584

9.  Injection of methylene blue solution into the inferior mesenteric artery of resected rectal specimens for rectal cancer as a method for increasing the lymph node harvest.

Authors:  E Klepšytė; N Evaldas Samalavičius
Journal:  Tech Coloproctol       Date:  2012-03-17       Impact factor: 3.781

10.  Rectal cancer staging.

Authors:  James S Wu
Journal:  Clin Colon Rectal Surg       Date:  2007-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.